US 12,268,720 B2
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
Sandra P. Morales, Sydney (AU); and Igor P. Bilinsky, San Diego, CA (US)
Assigned to Armata Pharmaceuticals, Inc., Marina del Rey, CA (US)
Appl. No. 16/968,132
Filed by Armata Pharmaceuticals, Inc., Marina del Rey, CA (US)
PCT Filed Feb. 7, 2019, PCT No. PCT/US2019/017129
§ 371(c)(1), (2) Date Aug. 6, 2020,
PCT Pub. No. WO2019/157231, PCT Pub. Date Aug. 15, 2019.
Claims priority of provisional application 62/627,725, filed on Feb. 7, 2018.
Prior Publication US 2021/0369798 A1, Dec. 2, 2021
Int. Cl. A61K 35/768 (2015.01); A61K 45/06 (2006.01); C12N 7/00 (2006.01)
CPC A61K 35/768 (2013.01) [A61K 45/06 (2013.01); C12N 7/00 (2013.01); C12N 2795/10132 (2013.01); C12N 2795/10332 (2013.01)] 24 Claims
 
1. A method of treating a bacterial associated cancer bacterial infection in a patient, the method comprising administering to the patient a composition comprising at least two obligately lytic bacteriophages that infect and lyse a bacterium, and wherein
a) the bacteriophages are selected from Ec34 (SEQ ID NO:2), Ec35 (SEQ ID NO:3), Ec45 (SEQ ID NO:4), and Ec57 (SEQ ID NO:6), and wherein the target bacteria are Escherichia coli; or
b) wherein the bacteriophages are selected from Bf1 (deposited with the International Depositary Authority of Canada under Accession No. 040219-02), Bf2 (deposited with the International Depositary Authority of Canada under Accession No. 040219-03), Bf3 (deposited with the International Depositary Authority of Canada under Accession No. 040219-04), and Bf4 (deposited with the International Depositary Authority of Canada under Accession No. 040219-05) and wherein the target bacteria are Bacteroides fragilis.